Critical Review: Prourocare Medical (PUMD) versus Atrion (ATRI)

Atrion (NASDAQ:ATRI) and Prourocare Medical (OTCMKTS:PUMD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

Dividends

Atrion pays an annual dividend of $5.40 per share and has a dividend yield of 0.6%. Prourocare Medical does not pay a dividend. Atrion has raised its dividend for 16 consecutive years.

Volatility & Risk

Atrion has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Prourocare Medical has a beta of 7.5, suggesting that its share price is 650% more volatile than the S&P 500.

Institutional and Insider Ownership

61.7% of Atrion shares are owned by institutional investors. 22.5% of Atrion shares are owned by company insiders. Comparatively, 29.3% of Prourocare Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Atrion and Prourocare Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atrion 22.47% 16.98% 15.35%
Prourocare Medical N/A N/A N/A

Valuation & Earnings

This table compares Atrion and Prourocare Medical’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Atrion $152.45 million 10.91 $34.26 million N/A N/A
Prourocare Medical N/A N/A N/A N/A N/A

Atrion has higher revenue and earnings than Prourocare Medical.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Atrion and Prourocare Medical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrion 0 0 0 0 N/A
Prourocare Medical 0 0 0 0 N/A

Summary

Atrion beats Prourocare Medical on 7 of the 9 factors compared between the two stocks.

Atrion Company Profile

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise MPS2 Myocardial Protection System that delivers fluids and medications, mixes critical drugs, and controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Prourocare Medical Company Profile

ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System. ProUroCare Medical Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.